German Funds "Must Explain Charges"

4 May 1997

German pharmacists already face patients' anger in advance of a rise indrug prescription charges from July 1. In reaction, the president of the national pharmacists' federation, Hans-Guenter Friese, has urged the health funds to explain the rises to their members, especially as some funds' charges are due to rise still further three months later.

Mr Friese says the Barmer supplementary fund members, for example, are being given too high expectations of the health service, which then rebound on pharmacists. The difference between the drug's ex-factory and retail price serves not only its trading and commercialization, he says, but also underpins functions including the emergency service which pharmacies are legally obliged to maintain, for which they get 2 Deutschemarks ($1.06) per item sold during 8pm-7am. This service is now inadequately funded, he says.

Large stock holdings are also underfunded under the present system, he says, although pharmacies stock, on average, 8,000-14,000 drugs in various forms. The federation expects the latest phase of reform to trigger a decline in drug sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight